Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBT Margin (2023 - 2025)

Historic EBT Margin for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to 2623.53%.

  • CG Oncology's EBT Margin rose 448253100.0% to 2623.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 6963.71%, marking a year-over-year increase of 36779600.0%. This contributed to the annual value of 7729.76% for FY2024, which is 160668100.0% up from last year.
  • According to the latest figures from Q3 2025, CG Oncology's EBT Margin is 2623.53%, which was up 448253100.0% from 66263.46% recorded in Q1 2025.
  • CG Oncology's EBT Margin's 5-year high stood at 2623.53% during Q3 2025, with a 5-year trough of 1655100.0% in Q4 2023.
  • Over the past 3 years, CG Oncology's median EBT Margin value was 17036.04% (recorded in 2024), while the average stood at 214864.91%.
  • Its EBT Margin has fluctuated over the past 5 years, first surged by 2000000000bps in 2024, then tumbled by -630640300bps in 2025.
  • Quarter analysis of 3 years shows CG Oncology's EBT Margin stood at 1655100.0% in 2023, then surged by 100bps to 6974.56% in 2024, then soared by 62bps to 2623.53% in 2025.
  • Its EBT Margin stands at 2623.53% for Q3 2025, versus 66263.46% for Q1 2025 and 6974.56% for Q4 2024.